Objective: Depression is a global and growing health issue. Complementary and alternative medicines (CAM) use is common among people with depression. We examined the baseline use of CAM (products, not services) in centrally obese adults with depression, a specific and increasingly important population who were part of a trial of Tai Chi and Qigong for depression. Methods: Self-reported use of CAM products (four major groups: vitamins, herbal medicines, mineral supplements and purified chemicals as nutritional supplements) together with demographic, lifestyle and health status characteristics were collected using validated questions within a written survey. We used descriptive statistics to understand patterns of use.
Introduction
Depression is a common serious and chronic illnesses with an estimated 350 million people of all ages affected worldwide. 1 Depression is an independent risk factor for heart disease 2 with growing evidence of a bidirectional relationship between depression and a range of physical illnesses, especially heart disease, stroke, type 2 diabetes (T2D), cancer, arthritis, osteoporosis, and obesity. 3, 4 Findings from the World Health Organization (WHO)'s World Health Survey indicate that depression is a leading cause of disability 5 ; it is associated with the greatest decrement in health of any chronic disease, and co-morbid depression incrementally worsens other health problems more than many other disease combinations. 5, 6 In addition, the WHO Longitudinal Investigation of Depression Outcomes study has reported that depression is associated with a 17%e46% increase in health costs. 5, 7 Almost half (45%) of Australians aged 16e85 years had a lifetime mental disorder and one in five (20%) has a disorder within the previous 12 months. 8 Furthermore, depression is associated with central obesity, which has been linked to an increased risk for cardiovascular disease and diabetes. Therefore, management of depression, especially in depressed adults with central obesity is important to public health.
Complementary and alternative medicines (CAM) are widely used in Australia. While there is no standardized classification of such products, commonly used CAM products include natural and herbal medicines; nutritional supplements, traditional remedies and vitamins and minerals. 9e13 CAM were the second mostly commonly used medicine class (after antihypertensive agents) in a national snapshot of medicine usage in adults aged 50 years and older. 14 People who have depression and anxiety use CAM as well as conventional therapies. 15 People with diabetes also use CAM based on studies in the US 16 and Taiwan. 17 Furthermore, there is a two-way association between depression and T2D as shown in a study involving more than 65 000 women. 18 People use complementary and integrative therapies because they may have a proclivity toward a holistic health focus and therefore are motivated to seek self-management strategies consistent with their beliefs.
Others often seek alternative treatments because they are experiencing a disabling condition for which they have not been able to find appropriate relief, or are experiencing significant side effects from traditional pharmacotherapeutic treatments. 19 The aim of this study was to describe the use of CAM products consumed by men and women with depression and central obesity, a significant contributor to T2D, who consented to participate in a Tai Chi and Qigong trial. 20 
Methods

Study design and sample
Study methods and ethics approval have been described elsewhere. 20 This study was approved by the Human Research Ethics Committees of the University of Queensland and the Princess Alexandra Hospital, in Brisbane, Australia. The clinical study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12613000010796). Briefly, voluntary participants were recruited between October 2009 and March 2010 using a range of methods. Eligibility criteria included age 18e80 years, a general practitioner's (GP) diagnosis of depression, taking antidepressants for depression or having a short-form Center for Epidemiologic Studies Depression Scale 10 (CES-D10) rating score of 10 or higher, 21, 22 and having central obesity assessed by waist circumference (>95 cm, men; 80 cm, women) and/or body mass index (BMI) > 30 kg/m 2 (the International Diabetes Federation 23 ). Exclusion criteria included contraindications to physical activity, mental illness other than depression, such as diagnosed bipolar disorder and schizophrenia, any severe or acute general medical illness that impacted on the capacity to participate or continue in the study, type 1 diabetes, current pregnancy, being within 3 months post-partum, or anticipating pregnancy during the course of the study. Initially, 1602 individuals responded to the study recruitment. We screened 536 respondents by telephone, of whom, 290 were potentially eligible and were invited to attend the screening assessment, where 260 attended the assessment.
Measures
Demographic and lifestyle characteristics Study participants were asked a variety of demographic questions in a survey at baseline which included gender, age, marital status, education level, employment status, occupation and ethnicity group by country. Participants were also asked about their use of a prescription antidepressant for depression, caffeinated drinks, alcohol use, and tobacco smoking with an answer of yes or no required in a written survey.
Health status characteristics Self-reported general health was assessed using the Medical Outcomes Study (MOS) SF36 Survey. 24, 25 Participants were asked about the presence of comorbid conditions including arthritis or rheumatism, diabetes, heart disease, hypertension, stroke and lung disease.
The severity of depressive, anxiety and stress symptoms was assessed by the CES-D 10 and the Depression Anxiety Stress Scale 21 (DASS 21). The CES-D 10 is a well-validated measure of the severity of depression. 21, 22 Total score ranges from 0 to 30, with higher scores indicating more severe depression. The DASS 21 is a well-validated measure of the severity of depression, anxiety and stress. 26e28 Total score ranges from 0 to 42 for depression, anxiety or stress, with higher scores indicating more severe depression, anxiety or stress (depression: 0e9 normal; mild anxiety 8e9; and extremely severe stress !34 for example).
Central obesity was defined by a waist circumference as >95 cm (men); 80 cm (women) and/or BMI >30 kg/m 2 . 23 BMI was calculated using the formula: BMI Z weight (kg)/ [height (m)] 2 . The measurements were conducted using standardized processes and obtained by an independent senior clinical nurse at the Princess Alexandra Hospital, Brisbane, Australia.
CAM use and classification
Participants were asked at baseline about their current use of CAM products and the conditions of such use using an open question in a written survey. The 67 reported different CAM products were subsequently categorized into four major groups including vitamins, herbal medicines, mineral supplements, and purified chemical as nutritional supplements, where these groups were modified from previous studies. 9,10 All CAM use was noted i.e. the sum of all four CAM groups. Some participants reported using CAM such as aromatherapy oils, soy products, Chinese medicine and homeopathic medicine, but owing to small numbers these groups were not further considered. The conditions for which CAM products were used were classified into 12 main categories based on published criteria. 9
Statistical analysis
We compared the characteristics of this sample and the Australian population using chi-square goodness-of-fit tests. In cases where population data were available on a limited number of categories, sample categories were collapsed to allow the tests to be done. Univariate logistic regression was used to examine the demographic and lifestyle predictors of CAM product use, for any CAM use and the four major product groups separately. Multivariate logistic regression was used to examine the association between CAM use and health status characteristics, after adjusting for demographic and lifestyle predictors found to be significant from the univariate analyses. Results are presented as percentages of CAM use by participant characteristics and 95% confidence intervals. P-values are derived from the corresponding logistic regression analyses, in which each category is compared to a reference category.
Results
Characteristics of the participants
The participants' demographics (n Z 260) varied somewhat from those in the Australian population as would be expected for depressed people with substantial central obesity. 29 They were more likely to be older, female and rate their health worse than the general population (Table 1 ).
Prevalence and predictors of CAM use
Nearly half of the participants were taking at least one form of CAM (n Z 129, 49.6%). Each of the 260 participants was taking, on average, 1.15 (SD Z 1.66) forms of CAM. Of those taking at least one CAM (n Z 129), the average number of CAM products was 2.31 (SD Z 1.70). The use of CAMs was investigated for demographic, lifestyle and health status characteristics for any CAM use and the four main categories of CAM. Women were more likely than men to use any CAM (56%, 34% respectively) ( Table 2) . Similarly, older people (aged 60 years or older) were more likely than those aged under 40 years to take any CAM (56% and 37%, respectively) including herbal medicines. Those who identified as non-Australian were less likely to use herbal medicines compared to those who identified as Australian ( Table 2) . People in a managerial or professional role were more likely to take herbal medicines compared to those in other occupations.
When considering lifestyle characteristics, there were no associations among CAM use and self-reported health or other risk factors such as smoking, alcohol use and obesity (note that participants already had some central obesity) nor the self-reported use of a prescription antidepressant medicine ( Table 3) . Self-reported comorbidities such as arthritis, diabetes or hypertension were not associated with CAM use. Those who were depressed (as measured by DASS) used less herbal medicines compared to those who had no DASS-reported depression ( Table 3) .
Reasons for CAM use
The patients' self-reported reasons for the use of any CAM products were mostly for general health and musculoskeletal conditions (e.g. general 'aches and pains', Table 4 ). In addition, stress, anxiety or insomnia were the main reasons for taking vitamins whereas herbal medicines were preferred for conditions related to blood circulation and blood sugar control. Both mineral and nutritional supplements were used mainly for musculoskeletal symptoms.
Discussion
This study has shown that in a community based population with moderate to severe depression, half used CAM products. On average, people reported using more than two forms of CAM products concurrently and for a wide range of health purposes. Women were more likely than men and older people more likely than younger people to use any CAM product, CAM as vitamins or CAM as herbal medicines. CAM use was not associated with self-reported health, risk factors (e.g. smoking and alcohol use), self-reported use of a prescription antidepressant medicine, nor comorbidities such as arthritis, diabetes or hypertension. People reported using CAM mostly for general health and alleviating 'aches and pains'.
Our findings of half of our participants using CAM products are consistent with previous studies in a non-depressed population in Australia: 53% 9 and 69%. 11, 13 The gender bias in use found in this analysis is comparable to previous Australian studies. 9, 11, 13, 30 The higher use in older people in our study is different to the profile seen in the general population where use was highest in the younger ages. 9, 11, 13 This increased use in older people in our study may be attributed to our participants being depressed and is a concern as, although the CAM evidence base overall is weak, it is even weaker in the older population. 13 Our study recruited people with depression and obesity, a contributor to T2D. People with T2D are known to have a higher use of CAM than the general population. For example, in Queensland, one in twelve people with T2D used a CAM practitioner in the previous 12 months. 30 Over half of a US population with T2D reported using CAM in a US study. 16 Overall, CAM use measured in a medical setting is likely to be underestimated as studies have shown low reporting to health care professionals. 17 The concurrent use of CAM products and medications for the treatment of depression and obesity may represent a risk but little data are available to determine the level of risk. In this study it is unknown how many participants disclosed their CAM use to their doctors, with the literature indicating doctors are often unaware of their patient's use of CAM. 11, 17 Doctors may be concerned that discussion of the interactions or the effect on their disease may result in the patient stopping their prescribed medicine(s). 31 Concurrent use of specific CAM products may have an impact on the management of the use of prescribed medicines. For example, St John's Wort has a similar mechanism of action to tricyclic antidepressants (TCA). 32 Hence, people taking both may be increasing their effective dose of the TCA and this exposes the patient to additional risk. Other antidepressants, together with St John's Wort, have caused serotonergic syndrome. 32 While there are inadequate data available on the interactions between CAM products and pharmacotherapies, the extent of the interaction may depend on many factors such as the actual dose of the herb and drug ingested by the patient, personal circumstances such as pregnancy, kidney and liver conditions, age and gender. 31 Our data highlight the importance of establishing whether depressed patients are using CAM at the time of assessment.
It is important to fully understand the efficacy of CAM modalities for the treatment of depression. Both direct supportive interactions between a health care practitioner and the consumer and the use of antidepressant therapy can help depressed people to improve their quality of life. 33 The patients' belief in the effectiveness of a medication was a unique factor that contributed to improvement. 33 This belief in the 'power' or effectiveness of the medicine may contribute to placebo responses in the treatment of depression and may extend to CAM products and modalities which have limited evidence of efficacy. While no specific questions were asked concerning the perceived benefit of the use of CAM products by participants with depression, CAM use is reported to be associated with perceived mental health needs, 34 the desire for a 'natural approach' and wanting treatment to be consistent with their own values and beliefs. 35 A qualitative evaluation found the choice of treatment was based largely on the type of illness, with those having chronic illness more likely to use CAM. 36 The strength of this study is that it was community based and therefore reflects a real world heterogeneous population of adults with depression and central obesity in the community. Furthermore, due to the depth of the survey, we could examine any CAM use or specific categories of CAM use associated with a variety of demographic, lifestyle and health status characteristics and their reasons for use. The method of selecting people with depression in the community could be seen as a limitation as we recruited people identified by their GPs as depressed and being on antidepressants for depression and/or who had depression scores above a pre-determined threshold. This included people with a range of depressive disorders. While this may potentially limit the generalizability of our findings to a specific diagnostic category of depression, such as major depressive disorder or resistant depressions, our findings are relevant to the population of depressed patients seen in primary care. Documentation of the reasons for use is also potentially difficult as each particular CAM product, even with the same active ingredient has a variety of labeling and uses. In addition, people often reported using CAM for general symptoms such as general aches and pains rather than for any specific or diagnosed condition.
Conclusion
The use of CAM modalities to ameliorate mood disorders such as depression continues to be underpinned by patient expectations for an improved quality of life. In this regard it would seem that patients have a preference for taking CAM therapies available without the rigorous testing required for standard depression therapies, and instead of evidence based versus face-to-face supportive care. Numerous CAM therapies used by participants in this study have low or no levels of evidence of efficacy, and many are known to have batch variations in active constituents 37 or the use of adulterants or substitutes. 38 There is a much uncertainty regarding the quality, effectiveness (generally not show in randomized clinical trials) and standardization and consistency of dose of CAM. Furthermore, there is a lack of knowledge regarding the side effects and interactions for some, although it is well known for others (e.g. St John's Wort). The use of CAM products in substantial, while the benefit and risk associated with concurrent use is yet to be determined. The extensive use of CAMs in depression as shown in this 'real world' study, and their known impact on the pharmacology of antidepressants, highlights the importance of establishing whether depressed patients are using CAM at the time of assessment. Given this context, it is important that clinicians are aware of this and can educate their patients. It is also important that further qualitative studies of CAM in depression are undertaken with relevant mental health endpoints and length of study. Table 4 The conditions for which CAM was used as given by study participants for any CAM and specified classes of CAM (n Z 292).
Conditions
Any CAM Vitamins Herbal medicine Mineral supplements Nutritional supplements Indooroopilly, and Saint Andrew's Uniting Church for providing tai chi exercise venues for the study.
